Lyell Immunopharma, Inc. (LYEL)
NASDAQ: LYEL · Real-Time Price · USD
0.5202
-0.0210 (-3.88%)
Mar 31, 2025, 1:27 PM EDT - Market open
Lyell Immunopharma Employees
Lyell Immunopharma had 300 employees as of December 31, 2024. The number of employees increased by 76 or 33.93% compared to the previous year.
Employees
300
Change (1Y)
76
Growth (1Y)
33.93%
Revenue / Employee
$203
Profits / Employee
-$1,143,313
Market Cap
153.58M
Employees Chart
Employees History
| Date | Employees | Change | Growth |
|---|---|---|---|
| Dec 31, 2024 | 300 | 76 | 33.93% |
| Dec 31, 2023 | 224 | -50 | -18.25% |
| Dec 31, 2022 | 274 | 55 | 25.11% |
| Dec 31, 2021 | 219 | 29 | 15.26% |
| Dec 31, 2020 | 190 | - | - |
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Thermo Fisher Scientific | 125,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 92,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
LYEL News
- 19 days ago - Lyell Immunopharma Reports Business Highlights and Financial Results for the Fourth Quarter and Full Year 2024 - GlobeNewsWire
- 5 weeks ago - Lyell Immunopharma Announces Participation in Upcoming Investor Conferences - GlobeNewsWire
- 2 months ago - Lyell to Highlight Vision for its Next-Generation CAR T-Cell Therapy Pipeline at 43rd Annual JP Morgan Healthcare Conference - GlobeNewsWire
- 3 months ago - Lyell Presents Positive Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the Treatment of B-cell Lymphoma at the 2024 ASH Annual Meeting - GlobeNewsWire
- 5 months ago - Lyell Announces Presentation of Initial Clinical Data from the Phase 1-2 Clinical Trial of IMPT-314 for the treatment of B-cell Lymphoma at the 2024 American Society of Hematology (ASH) Annual Meeting - GlobeNewsWire
- 5 months ago - Lyell Immunopharma Completes Acquisition of ImmPACT Bio - GlobeNewsWire
- 5 months ago - Lyell Immunopharma: Oversold And Poised For A Turning Point To Growth - Seeking Alpha
- 5 months ago - Lyell Immunopharma to Acquire ImmPACT Bio and Prioritizes its Pipeline to Focus on Next-Generation CAR T-cell Therapies - GlobeNewsWire